Drugs & Aging

, Volume 25, Issue 3, pp 219–239 | Cite as

Clinical Features, Differential Diagnosis and Treatment of Autoimmune Hepatitis in the Elderly

Review Article


Autoimmune hepatitis affects all ages, and it is probably under-diagnosed in the elderly. Patients aged ≥60 years have a higher frequency of cirrhosis at presentation than adults aged ≤30 years, and they more commonly have HLA DRB1*04. These findings suggest that host factors affect the clinical phenotype by influencing the antigens that are presented to immunocytes and the nature of the immune response. The elderly may have an indolent progressive disease that is asymptomatic or masked by other concurrent rheumatic conditions. An acute, even fulminant, presentation may reflect de novo disease or a spontaneous exacerbation of a pre-existent chronic process. Centrilobular (zone 3) necrosis may reflect an early histological stage that transforms later to classical interface hepatitis. Diagnostic criteria have been codified, and a scoring system allows systemic assessment of all clinical features and quantifies the strength of the diagnosis. Prednisone in combination with azathioprine is the safest effective initial treatment, and all elderly patients with severe disease should be treated vigorously to full resolution of clinical, laboratory and histological features. Adverse effects of treatment occur mainly with protracted treatment (>18 months) and repeated therapies after relapse. Adjustments in the management strategy are warranted for an incomplete response or a need for re-treatment after relapse. Azathioprine (2 mg/kg/day) should be used as a corticosteroid-sparing, long-term maintenance therapy in these instances. Treatment failure is uncommon in the elderly, and age-related changes in the cellular immune response may attenuate the disease and enhance its response to therapy. Concurrent adjuvant therapies must focus on maintenance of bone density.



No sources of funding were used to assist in the preparation of this review. The author has no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Czaja AJ. Current concepts in autoimmune hepatitis. Ann Hepatol 2005; 4: 6–24PubMedGoogle Scholar
  2. 2.
    Czaja AJ. Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol Dietol 2005; 51: 313–33PubMedGoogle Scholar
  3. 3.
    Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 2001; 96: 1224–31PubMedCrossRefGoogle Scholar
  4. 4.
    Czaja AJ. Treatment of autoimmune hepatitis. Semin Liver Dis 2002; 22: 365–77PubMedCrossRefGoogle Scholar
  5. 5.
    Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929–38PubMedCrossRefGoogle Scholar
  6. 6.
    Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36: 479–97PubMedCrossRefGoogle Scholar
  7. 7.
    Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006; 43: 532–8PubMedCrossRefGoogle Scholar
  8. 8.
    Parker DR, Kingham JGC. Type 1 autoimmune hepatitis is primarily a disease of later life. Q J Med 1997; 90: 289–96CrossRefGoogle Scholar
  9. 9.
    Schramm C, Kanzler S, Meyer zum Buschenfelde K-H, et al. Autoimmune hepatitis in the elderly. Am J Gastroenterol 2001; 96: 1587–91PubMedCrossRefGoogle Scholar
  10. 10.
    Granito A, Muratori L, Pappas G, et al. Clinical features of type 1 autoimmune hepatitis in elderly Italian patients. Aliment Pharmacol Ther 2005; 21: 1273–7PubMedCrossRefGoogle Scholar
  11. 11.
    Al-Chalabi T, Boccato S, Portmann BC, et al. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral center. J Hepatol 2006; 45: 575–83PubMedCrossRefGoogle Scholar
  12. 12.
    Newton JL, Burt AD, Park JB, et al. Autoimmune hepatitis in older patients. Age Aging 1997; 26: 441–4CrossRefGoogle Scholar
  13. 13.
    Verslype C, George C, Buchel E, et al. Diagnosis and treatment of autoimmune hepatitis at age 65 and older. Aliment Pharmacol Ther 2005; 21: 695–9PubMedCrossRefGoogle Scholar
  14. 14.
    Miyake T, Miyaoka H, Abe M, et al. Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol Res 2006; 36: 139–42PubMedCrossRefGoogle Scholar
  15. 15.
    Lebovics E, Schaffner F, Klion EM, et al. Autoimmune chronic active hepatitis in postmenopausal women. Dig Dis Sci 1985; 30: 824–8PubMedCrossRefGoogle Scholar
  16. 16.
    Wang KK, Czaja AJ. Prognosis of corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis in post-menopausal women: a retrospective analysis. Gastroenterology 1989; 97: 1288–93PubMedGoogle Scholar
  17. 17.
    Czaja AJ. Treatment strategies in autoimmune hepatitis. Clin Liver Dis 2002; 6: 799–824PubMedCrossRefGoogle Scholar
  18. 18.
    Strassburg CP, Manns MP. Autoimmune hepatitis in the elderly: what is the difference? J Hepatol 2006; 45: 480–2PubMedCrossRefGoogle Scholar
  19. 19.
    Vergani D, Choudhuri K, Bogdanos DP, et al. Pathogenesis of autoimmune hepatitis. Clin Liver Dis 2002; 6: 727–37PubMedCrossRefGoogle Scholar
  20. 20.
    Czaja AJ. Evolving concepts in the diagnosis, pathogenesis and treatment of autoimmune hepatitis. Minerva Gastroenterol Dietol 2007; 53: 43–78PubMedGoogle Scholar
  21. 21.
    Bach J-F. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002; 347: 911–20PubMedCrossRefGoogle Scholar
  22. 22.
    Vrieling H, Tates AD, Natarajan AT, et al. Age-related accumulation of mutations in human T-lymphocytes. Ann N Y Acad Sci 1992; 663: 36–42PubMedCrossRefGoogle Scholar
  23. 23.
    Doherty DG, Penzotti JE, Koelle DM, et al. Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. J Immunol 1998; 161: 3527–35PubMedGoogle Scholar
  24. 24.
    Schwab R, Russo C, Weksler ME. Altered major histocompatibility complex-restricted antigen recognition by T cells from elderly humans. Eur J Immunol 1992; 22: 2989–93PubMedCrossRefGoogle Scholar
  25. 25.
    De Paoli P, Battistin S, Santini GF. Age-related changes in human lymphocyte subsets: progressive reduction of the CD4 CD45R (suppressor inducer) population. Clin Immunol Immunopathol 1988; 48: 290–6PubMedCrossRefGoogle Scholar
  26. 26.
    Murasko DM, Goonewardene IM. T cell function in aging: mechanisms of decline. Ann Rev Gerontol Geriatr 1990; 10: 71–96Google Scholar
  27. 27.
    Paganelli R, Quinti I, Fagiolo U, et al. Changes in circulating B cells and immunoglobulin classes and subclasses in a healthy aged population. Clin Exp Immunol 1992; 90: 351–4PubMedCrossRefGoogle Scholar
  28. 28.
    Rowley MJ, Buchanan H, Mackay IR. Reciprocal change with age in antibodies to extrinsic vs. intrinsic antigens. Lancet 1968; II: 24–6CrossRefGoogle Scholar
  29. 29.
    Hooper B, Whittingham S, Mathews JD, et al. Autoimmunity in a rural community. Clin Exp Immunol 1972; 12: 79–87PubMedGoogle Scholar
  30. 30.
    Talor E, Rose NR. Hypothesis: the aging paradox and autoimmune disease. Autoimmunity 1991; 8: 245–9PubMedCrossRefGoogle Scholar
  31. 31.
    Currie MS. Immunosenescence. Compr Ther 1992; 18: 26–34PubMedGoogle Scholar
  32. 32.
    Ben-Yehuda A, Weksler ME. Immune senescence: mechanisms and clinical implications. Cancer Invest 1992; 10: 525–31PubMedCrossRefGoogle Scholar
  33. 33.
    Czaja AJ. Autoantibodies in autoimmune liver disease. Adv Clin Chem 2005; 40: 127–64PubMedCrossRefGoogle Scholar
  34. 34.
    Singh R, Nair S, Farr G, et al. Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature. Am J Gastroenterol 2002; 97: 2670–3PubMedCrossRefGoogle Scholar
  35. 35.
    Okano N, Yamamoto K, Sakaguchi K, et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res 2003; 25: 263–70PubMedCrossRefGoogle Scholar
  36. 36.
    Misdraji J, Thiim M, Graeme-Cook FM. Autoimmune hepatitis with centrilobular necrosis. Am J Surg Pathol 2004; 28: 471–8PubMedCrossRefGoogle Scholar
  37. 37.
    Kanda T, Yokosuka O, Hirasawa Y, et al. Acute-onset autoimmune hepatitis resembling acute hepatitis: a case report and review of reported cases. Hepatogastroenterology 2005; 52: 1233–5PubMedGoogle Scholar
  38. 38.
    Kessler WR, Cummings OW, Eckert G, et al. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004; 2: 625–31PubMedCrossRefGoogle Scholar
  39. 39.
    Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994; 21: 866–71PubMedCrossRefGoogle Scholar
  40. 40.
    Burgart LJ, Batts KP, Ludwig J, et al. Recent onset autoimmune hepatitis: biopsy findings and clinical correlations. Am J Surg Path 1995; 19: 699–708PubMedCrossRefGoogle Scholar
  41. 41.
    Keating JJ, O’Brien CJ, Stellon AJ, et al. Influence of aetiology, clinical, and histological features on survival in chronic active hepatitis: an analysis of 204 patients. Q J Med 1987; 62: 59–66PubMedGoogle Scholar
  42. 42.
    Czaja AJ. Autoimmune hepatitis: clinical and laboratory diagnosis. In: Dienes H-P, Leuschner U, Lohse AW, et al., editors. Autoimmune liver disease: Falk symposium no. 142. Dordrecht: Springer, 2005: 153–70CrossRefGoogle Scholar
  43. 43.
    Hay JE, Czaja AJ, Rakela J, et al. The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology 1989; 9: 193–7PubMedCrossRefGoogle Scholar
  44. 44.
    Kogan J, Safadi R, Ashur Y, et al. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 2002; 35: 75–81PubMedCrossRefGoogle Scholar
  45. 45.
    Feld JJ, Dinh H, Arenovich T, et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42: 53–62PubMedCrossRefGoogle Scholar
  46. 46.
    Czaja AJ, Carpenter HA, Santrach PJ, et al. Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 1993; 18: 816–22PubMedCrossRefGoogle Scholar
  47. 47.
    Czaja AJ, Carpenter HA, Santrach PJ, et al. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993; 105: 1502–7PubMedCrossRefGoogle Scholar
  48. 48.
    Czaja AJ, Dos Santos RM, Porto A, et al. Immune phenotype of chronic liver disease. Dig Dis Sci 1998; 43: 2149–55PubMedCrossRefGoogle Scholar
  49. 49.
    Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97: 2051–7PubMedCrossRefGoogle Scholar
  50. 50.
    Volta U, De Franceschi L, Molinaro N, et al. Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Dig Dis Sci 1998; 43: 2190–5PubMedCrossRefGoogle Scholar
  51. 51.
    Villalta D, Girolami D, Bidoli E, et al. High prevalence of celiac disease in autoimmune hepatitis detected by anti-tissue transglutaminase autoantibodies. J Clin Lab Anal 2005; 19: 6–10PubMedCrossRefGoogle Scholar
  52. 52.
    Abraham S, Begum S, Isenberg D. Hepatic manifestations of autoimmune rheumatic diseases. Am Rheum Dis 2004; 63: 123–9CrossRefGoogle Scholar
  53. 53.
    Donaldson PT, Doherty DG, Hayllar KM, et al. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991; 13: 701–6PubMedCrossRefGoogle Scholar
  54. 54.
    Montano-Loza A, Carpenter HA, Czaja AJ. Clinical significance of HLA DRB1*03-DRB1*04 in type 1 autoimmune hepatitis. Liver Int 2006; 26: 1201–8PubMedCrossRefGoogle Scholar
  55. 55.
    Strettell MDJ, Donaldson PT, Thomson LJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997; 112: 2028–35PubMedCrossRefGoogle Scholar
  56. 56.
    Czaja AJ, Strettell MDJ, Thomson LJ, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997; 25: 317–23PubMedCrossRefGoogle Scholar
  57. 57.
    Schreuder GM, Hurley CK, Marsh SG, et al. The HLA dictionary 2001: a summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and -DQ antigens. Hum Immunol 2001; 62: 826–49PubMedCrossRefGoogle Scholar
  58. 58.
    Seki T, Kiyosawa K, Inoko H, et al. Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients. Hepatology 1990; 12: 1300–4PubMedCrossRefGoogle Scholar
  59. 59.
    Seki T, Ota M, Furuta S, et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology 1992; 103: 1041–7PubMedGoogle Scholar
  60. 60.
    Yoshizawa K, Ota M, Katsuyama Y, et al. Genetic analysis of the HLA region of Japanese patients with type 1 autoimmune hepatitis. J Hepatol 2005; 42: 578–84PubMedCrossRefGoogle Scholar
  61. 61.
    Qiu D-K, Ma X. Relationship between human leukocyte antigen-DRB1 and autoimmune hepatitis type I in Chinese patients. J Gastroenterol Hepatol 2003; 18: 63–7PubMedCrossRefGoogle Scholar
  62. 62.
    Vazquez-Garcia MN, Alaez C, Olivo A, et al. MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J Hepatol 1998; 28: 985–90PubMedCrossRefGoogle Scholar
  63. 63.
    Muratori P, Czaja AJ, Muratori L, et al. Genetic distinctions between autoimmune hepatitis in Italy and North America. World J Gastroenterol 2005; 11: 1862–6PubMedGoogle Scholar
  64. 64.
    Fainboim L, Marcos Y, Pando M, et al. Chronic active autoimmune hepatitis in children: strong association with a particular HLA DR6 (DRB1*1301) haplotype. Hum Immunol 1994; 41: 146–50PubMedCrossRefGoogle Scholar
  65. 65.
    Nakamura K, Yoneda M, Yokohama S, et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998; 13: 490–5PubMedCrossRefGoogle Scholar
  66. 66.
    Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992; 103: 1290–5PubMedGoogle Scholar
  67. 67.
    Czaja AJ, Kruger M, Santrach PJ, et al. Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastroenterol 1997; 92: 2197–200PubMedGoogle Scholar
  68. 68.
    Bittencourt PL, Goldberg AC, Cancado ELR, et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol 1999; 94: 1906–13PubMedCrossRefGoogle Scholar
  69. 69.
    Djilali-Saiah I, Fakhfakh A, Louafi H, et al. HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis. J Hepatol 2006; 45: 844–50PubMedCrossRefGoogle Scholar
  70. 70.
    Czaja AJ, Carpenter HA, Moore SB. Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North America outside DR3 and DR4. Liver Int 2006; 26: 552–8PubMedCrossRefGoogle Scholar
  71. 71.
    Casali P, Schettino EW. Structure and function of natural antibodies. Curr Top Microbiol Immunol 1999; 210: 167–79CrossRefGoogle Scholar
  72. 72.
    Hayakawa K, Asano M, Shinton SA, et al. Positive selection of natural autoreactive B cells. Science 1999; 285: 113–6PubMedCrossRefGoogle Scholar
  73. 73.
    Tomer Y, Shoenfeld Y. The significance of natural autoantibodies. Immunol Invest 1988; 17: 389–424PubMedCrossRefGoogle Scholar
  74. 74.
    Czaja AJ, Manns MP. The validity and importance of subtypes of autoimmune hepatitis: a point of view. Am J Gastroenterol 1995; 90: 1206–11PubMedGoogle Scholar
  75. 75.
    Homberg J-C, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of “autoimmune” hepatitis. Hepatology 1987; 7: 1333–9PubMedCrossRefGoogle Scholar
  76. 76.
    Manns MP, Griffin KJ, Sullivan KF, et al. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cyto-chrome P-450 monooxygenase. J Clin Invest 1991; 88: 1370–8PubMedCrossRefGoogle Scholar
  77. 77.
    Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 1993; 105: 1522–8PubMedCrossRefGoogle Scholar
  78. 78.
    Granito A, Muratori L, Muratori P, et al. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J Clin Pathol 2006; 59: 280–4PubMedCrossRefGoogle Scholar
  79. 79.
    Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002; 35: 658–64PubMedCrossRefGoogle Scholar
  80. 80.
    Czaja AJ, Donaldson FT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors in type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97: 413–9PubMedCrossRefGoogle Scholar
  81. 81.
    Czaja AJ, Shums Z, Norman GL. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Autoimmunity 2002; 35: 475–83PubMedCrossRefGoogle Scholar
  82. 82.
    Czaja AJ, Cassani F, Cataleta M, et al. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996; 24: 1068–73PubMedCrossRefGoogle Scholar
  83. 83.
    McFarlane IG, Hegarty JE, McSorley CG, et al. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet 1984; II: 954–6CrossRefGoogle Scholar
  84. 84.
    Czaja AJ, Pfeifer KD, Decker RH, et al. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Dig Dis Sci 1996; 41: 1733–40PubMedCrossRefGoogle Scholar
  85. 85.
    Kenny RP, Czaja AJ, Ludwig J, et al. Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. Dig Dis Sci 1986; 31: 705–11PubMedCrossRefGoogle Scholar
  86. 86.
    Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998; 28: 360–5PubMedCrossRefGoogle Scholar
  87. 87.
    Lim KN, Casanova RL, Boyer TD, et al. Autoimmune hepatitis in African Americans: presenting features and responses to therapy. Am J Gastroenterol 2001; 96: 3390–4PubMedCrossRefGoogle Scholar
  88. 88.
    Hurlburt KJ, McMahon BJ, Deubner H, et al. Prevalence of autoimmune hepatitis in Alaska natives. Am J Gastroenterol 2002; 97: 2402–7PubMedCrossRefGoogle Scholar
  89. 89.
    Czaja AJ, Souto EO, Bittencourt PL, et al. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol 2002; 37: 302–8PubMedCrossRefGoogle Scholar
  90. 90.
    Zolfino T, Heneghan MA, Norris S, et al. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 2002; 50: 713–7PubMedCrossRefGoogle Scholar
  91. 91.
    D’Souza R, Sinnott P, Glynn MJ, et al. An unusual form of autoimmune hepatitis in young Somalian men. Liver Int 2005; 25: 325–30PubMedCrossRefGoogle Scholar
  92. 92.
    Gonazalez-Koch A, Czaja AJ, Carpenter HA, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001; 7: 302–10CrossRefGoogle Scholar
  93. 93.
    Heneghan MA, Portmann BC, Norris SM, et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 2001; 34: 464–70PubMedCrossRefGoogle Scholar
  94. 94.
    Seaberg EC, Belle SH, Beringer KC, et al. Liver transplantation in the United States from 1987 to 1998: updated results from the Pitt-UNOS liver transplant registry. In: Cecka JM, Terasaki PI, editors. Clinical transplants 1998. Los Angeles (CA): UCLA Tissue Typing Laboratories, 1999: 17–37Google Scholar
  95. 95.
    Salcedo M, Vaquero J, Banares R, et al. Response to steroids in de novo autoimmune hepatitis after transplantation. Hepatology 2002; 35: 349–56PubMedCrossRefGoogle Scholar
  96. 96.
    Demetris AJ, Adeyi O, Bellamy CO, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006; 44: 489–501PubMedCrossRefGoogle Scholar
  97. 97.
    Helfgott SM, Sandberg-Cook J, Zakim D, et al. Diclofenacassociated hepatotoxicity. JAMA 1990; 264: 2660–2PubMedCrossRefGoogle Scholar
  98. 98.
    Sharp JR, Ishak KG, Zimmerman HJ. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 1980; 92: 14–9PubMedGoogle Scholar
  99. 99.
    Germano V, Picchianti Diamanti A, Baccano G, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005; 64: 1519–20PubMedCrossRefGoogle Scholar
  100. 100.
    Herzog D, Hajoui O, Russo P, et al. Study of immune reactivity of minocycline-induced chronic active hepatitis. Dig Dis Sci 1997; 42: 1100–3PubMedCrossRefGoogle Scholar
  101. 101.
    Fedotin MS, Lefer LG. Liver disease caused by propylthiouracil. Arch Intern Med 1975; 135: 319–21PubMedCrossRefGoogle Scholar
  102. 102.
    Black M, Mitchell JR, Zimmerman HJ, et al. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975; 69: 289–302PubMedGoogle Scholar
  103. 103.
    Rodman JS, Deutsch DJ, Gutman SI. Methyldopa hepatitis: a report of six cases and review of the literature. Am J Med 1976; 60: 941–8PubMedCrossRefGoogle Scholar
  104. 104.
    Czaja AJ, Carpenter HA. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993; 105: 1824–32PubMedGoogle Scholar
  105. 105.
    Ludwig J, Czaja AJ, Dickson ER, et al. Manifestations of nonsuppurative cholangitis in chronic hepatobiliary disease: morphologic spectrum, clinical correlations and terminology. Liver 1984; 4: 105–16PubMedGoogle Scholar
  106. 106.
    Czaja AJ, Carpenter HA, Santrach PJ, et al. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000; 31: 1231–8PubMedCrossRefGoogle Scholar
  107. 107.
    Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001; 34: 659–65PubMedCrossRefGoogle Scholar
  108. 108.
    Soloway RD, Summerskill WHJ, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820–33PubMedGoogle Scholar
  109. 109.
    Schalm SW, Korman MG, Summerskill WHJ, et al. Severe chronic active liver disease: prognostic significance of initial morphologic patterns. Am J Dig Dis 1977; 22: 973–80PubMedCrossRefGoogle Scholar
  110. 110.
    Cooksley WGE, Bradbear RA, Robinson W, et al. The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis. Hepatology 1986; 6: 345–8PubMedCrossRefGoogle Scholar
  111. 111.
    Roberts SK, Therneau T, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110: 848–57PubMedCrossRefGoogle Scholar
  112. 112.
    Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40: 159–85PubMedGoogle Scholar
  113. 113.
    Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; I: 735–7CrossRefGoogle Scholar
  114. 114.
    Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004; 40: 644–50CrossRefGoogle Scholar
  115. 115.
    Summerskill WHJ, Korman MG, Ammon HV, et al. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975; 16: 876–83PubMedCrossRefGoogle Scholar
  116. 116.
    Czaja AJ. Low dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 1990; 11: 1044–9PubMedCrossRefGoogle Scholar
  117. 117.
    Johnson PJ, McFarlane IG, Williams R. Azathioprine for longterm maintenance of remission in autoimmune hepatitis. N Engl J Med 1995; 333: 958–63PubMedCrossRefGoogle Scholar
  118. 118.
    Verma S, Gunuwan B, Mendler M, et al. Factors predicting relapse and poor outcome in type 1 autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission, and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004; 99: 1510–6PubMedCrossRefGoogle Scholar
  119. 119.
    Miyake Y, Iwasaki Y, Terada R, et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 2005; 43: 951–7PubMedCrossRefGoogle Scholar
  120. 120.
    Montano-Loza A, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007; 102: 1005–12PubMedCrossRefGoogle Scholar
  121. 121.
    Czaja AJ, Beaver SJ, Shiels MT. Sustained remission following corticosteroid therapy of severe HBsAg-negative chronic active hepatitis. Gastroenterology 1987; 92: 215–9PubMedGoogle Scholar
  122. 122.
    Schalm SW, Ammon HV, Summerskill WHJ. Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res 1976; 8: 221–7PubMedGoogle Scholar
  123. 123.
    Langley PG, Underhill J, Tredger JM, et al. Thiopurine methyl-transferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol 2002; 37: 441–7PubMedCrossRefGoogle Scholar
  124. 124.
    Heneghan MA, Allan ML, Bornstein JD, et al. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006; 45: 584–91PubMedCrossRefGoogle Scholar
  125. 125.
    Czaja AJ, Carpenter HA. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci 2006; 51: 968–75PubMedCrossRefGoogle Scholar
  126. 126.
    Wang KK, Czaja AJ, Beaver SJ, et al. Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Hepatology 1989; 10: 39–43PubMedCrossRefGoogle Scholar
  127. 127.
    Uribe M, Go VLW, Kluge D. Prednisone for chronic active hepatitis: pharmacokinetics and serum binding in patients with chronic active hepatitis and steroid major side effects. J Clin Gastroenterol 1984; 6: 331–5PubMedGoogle Scholar
  128. 128.
    Czaja AJ, Davis GL, Ludwig J, et al. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984; 4: 622–7PubMedCrossRefGoogle Scholar
  129. 129.
    Czaja AJ, Ammon HV, Summerskill WHJ. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 1980; 78: 518–23PubMedGoogle Scholar
  130. 130.
    Hegarty JE, Nouri-Aria KT, Portmann B, et al. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983; 3: 685–9PubMedCrossRefGoogle Scholar
  131. 131.
    Czaja AJ, Menon KVN, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002; 35: 890–7PubMedCrossRefGoogle Scholar
  132. 132.
    Cross TJS, Antoniades CG, Muieson P, et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl 2007; 13: 1382–8PubMedCrossRefGoogle Scholar
  133. 133.
    Ratziu V, Samuel D, Sebagh M, et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 1999; 30: 131–41PubMedCrossRefGoogle Scholar
  134. 134.
    Hayashi M, Keefe EB, Krams SM, et al. Allograft rejection after liver transplantation for autoimmune liver disease. Liver Transpl Surg 1998; 4: 208–14PubMedCrossRefGoogle Scholar
  135. 135.
    Fernandes NF, Redeker AG, Vierling JM, et al. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999; 94: 241–8PubMedCrossRefGoogle Scholar
  136. 136.
    Malekzadeh R, Nasser-Moghaddam S, Kaviani M-J, et al. Cyclosporin-A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001; 46: 1321–7PubMedCrossRefGoogle Scholar
  137. 137.
    Vierling JM, Flores PA. Evolving new therapies of autoimmune hepatitis. Clin Liver Dis 2002; 6: 825–50PubMedCrossRefGoogle Scholar
  138. 138.
    Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995; 90: 771–6PubMedGoogle Scholar
  139. 139.
    Aqel BA, Machicao V, Rosser B, et al. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004; 38: 805–9PubMedCrossRefGoogle Scholar
  140. 140.
    Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis patients resistant to or intolerant of azathioprine. J Hepatol 2000; 33: 371–5PubMedCrossRefGoogle Scholar
  141. 141.
    Devlin SM, Swain MG, Urbanski SJ, et al. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004; 18: 321–6PubMedGoogle Scholar
  142. 142.
    Chatur N, Ramji A, Bain VG, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian Association for the Study of Liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005; 25: 723–7PubMedCrossRefGoogle Scholar
  143. 143.
    Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol 2005; 39: 819–25PubMedCrossRefGoogle Scholar
  144. 144.
    Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994; 8: 585–90PubMedCrossRefGoogle Scholar
  145. 145.
    Wiegand J, Schuller A, Kanzler S, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005; 25: 927–34PubMedCrossRefGoogle Scholar
  146. 146.
    Csepregi A, Rocken C, Treiber G, et al. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol 2006; 12: 1362–6PubMedGoogle Scholar
  147. 147.
    Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000; 119: 1312–6PubMedCrossRefGoogle Scholar
  148. 148.
    Geier A, Gartung C, Dietrich CG, et al. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol 2003; 9: 2681–5PubMedGoogle Scholar
  149. 149.
    de Boer NKH, van Nieuwkerk CMJ, Pages MNA, et al. Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine. Eur J Gastroenterol 2005; 17: 457–61CrossRefGoogle Scholar
  150. 150.
    Santos ES, Arosemena LR, Raez LE, et al. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of the literature. Liver Int 2006; 26: 625–9PubMedCrossRefGoogle Scholar
  151. 151.
    Kanzler S, Gerken G, Dienes HP, et al. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis: report of three cases. Z Gastroenterol 1997; 35: 571–8PubMedGoogle Scholar
  152. 152.
    Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998; 29: 990–3PubMedCrossRefGoogle Scholar
  153. 153.
    Rebollo Bernardez J, Cifuentes Mimoso C, Pinar Moreno A, et al. Deflazacort for long-term maintenance of remission in type 1 autoimmune hepatitis. Rev Esp Enferm Dig 1999; 91: 630–8PubMedGoogle Scholar
  154. 154.
    Carmassi F, Morale R, Puccetti R, et al. Efficacy of intravenous immunoglobulin therapy in a case of autoimmune-mediated chronic active hepatitis. Clin Exp Rheumatol 1992; 10: 13–7PubMedGoogle Scholar
  155. 155.
    Swada K, Ohnishi K, Kosaka T, et al. Exacerbated autoimmune hepatitis successfully treated with leukocytopheresis and bilirubin adsorption therapy. J Gastroenterol 1997; 32: 689–95CrossRefGoogle Scholar
  156. 156.
    Fridkis-Hareli M, Rosloniec EF, Fugger L, et al. Synthetic peptides that inhibit binding of the collagen type II 261–273 epitope to rheumatoid arthritis-associated HLA-DR1 and DR4 molecules and collagen-specific T-cell responses. Hum Immunol 2000; 61: 640–50PubMedCrossRefGoogle Scholar
  157. 157.
    Guinan EC, Boussiotis VA, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999; 340: 1704–14PubMedCrossRefGoogle Scholar
  158. 158.
    Wardrop RM, Whitacre CC. Oral tolerance in the treatment of inflammatory autoimmune diseases. Inflamm Res 1999; 48: 106–19PubMedCrossRefGoogle Scholar
  159. 159.
    Lohse AW, Dienes HP, Meyer zum Buschenfelde K-H. Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or immunosuppression. Hepatology 1998; 27: 1536–43PubMedCrossRefGoogle Scholar
  160. 160.
    Nelson DR, Lauwers GY, Lau JY, et al. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot study of Interferon nonresponders. Gastroenterology 2000; 118: 655–60PubMedCrossRefGoogle Scholar
  161. 161.
    Rutgeerts P, D’Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999; 117: 761–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Division of Gastroenterology and HepatologyMayo Clinic College of MedicineRochesterUSA

Personalised recommendations